| Identification | Back Directory | [Name]
(S)-BAY-293 | [CAS]
2244904-69-4 | [Synonyms]
BAY 294
(S)-BAY-293
BAY 293 Negative Control
4-Quinazolinamine, 6,7-dimethoxy-2-methyl-N-[(1S)-1-[4-[2-[(methylamino)methyl]phenyl]-2-thienyl]ethyl]- | [Molecular Formula]
C25H28N4O2S | [MOL File]
2244904-69-4.mol | [Molecular Weight]
448.58 |
| Chemical Properties | Back Directory | [Boiling point ]
553.4±50.0 °C(Predicted) | [density ]
1.218±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
9.61±0.10(Predicted) | [color ]
White to off-white | [optical activity]
[α]/D +86.0 to +106.0°, c =1.0 in DMSO |
| Hazard Information | Back Directory | [Uses]
(S)-BAY-293 is a negative control of BAY 293. BAY 293 is a potent KRAS-SOS1 interaction inhibitor[1]. | [Biological Activity]
BAY-294 corresponds to the (S)-enantiomer of and the recommended control for the selective SOS1-KRAS interaction inhibitor BAY-293 (IC50 = 2.34 μM/BAY-294 vs. 21 nM/BAY-293; 10 nM hSOS1c at & 5 nM hKRAS G12C). BAY-294 exhibits little potency against SOS1-mediated KRAS activation (IC50 = 3.91 μM/BAY-294 vs. 52 nM/BAY-293; 10 nM SOS1c at & 50 nM wt hKRAS). | [storage]
Store at -20°C | [References]
[1] Hillig RC, et, al. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction. Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2551-2560. DOI:10.1073/pnas.1812963116 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|